Medpace Holdings (MEDP) Cost of Revenue (2015 - 2026)

Medpace Holdings (MEDP) has reported Cost of Revenue for 12 consecutive years, with $505.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 19.47% year-over-year to $505.7 million; the trailing twelve-month figure through Jun 2026 stood at $2.0 billion (up 29.88% YoY), and the FY2025 full-year result was $1.8 billion, up 21.81% from the prior year.
• Cost of Revenue declined to $505.7 million in Q2 2026 per MEDP's latest filing, from $510.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $510.3 million in Q1 2026 and bottomed at $232.3 million in Q1 2022.
• Historically, Cost of Revenue has averaged $368.2 million across 5 years, with a median of $360.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue fell 0.92% in 2024, then surged 40.43% in 2025.
• Over 5 years, Cost of Revenue stood at $278.4 million in 2022, then grew by 29.9% to $361.6 million in 2023, then fell by 0.92% to $358.3 million in 2024, then soared by 40.43% to $503.1 million in 2025, then advanced by 0.51% to $505.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $505.7 million, $510.3 million, and $503.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.